ArticleDigestive diseases and sciences2026
Upadacitinib Is Safe and Effective in Older Adults: A Real-World Experience Comparing Safety and Efficacy in Younger Versus Older Adults with Inflammatory Bowel Disease.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients?Current opinion in lipidology · 2026Review
- Managing Acute Severe Ulcerative Colitis in the Older Patient: A Growing Concern.Drugs & aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUpadacitinib (UPA), a selective Janus kinase (JAK) inhibitor, is a small molecule approved for the treatment of ulcerative colitis (UC) and Crohn's disease (CD) with limited data in the older adult population. We compared the safety and efficacy of UPA between younger (< 50 years) and older (≥ 50 years) adults with moderate-to-severe UC.
methodsWe performed a single-center retrospective cohort study of adults treated with UPA monotherapy for UC between January 2015 and 2024. Demographic data, efficacy outcomes, and adverse events (AE) were collected over 24 months. Outcomes included were clinical response and remission assessed by partial Mayo score, endoscopic improvement, and histologic remission.
resultsParticipants totaled 120 (88 < 50 years and 32 ≥ 50 years). Age did not significantly impact clinical remission rates at 24 months (younger 55.7% vs older 53.1%, p = 0.80). Older patients had a significantly higher rate of both endoscopic (71.4% vs 34.2%, p < 0.05) and histologic remission (54.6% vs 16.7%, p < 0.05) at 24 months. Despite similar baseline severity levels, younger patients had a higher flare rate during maintenance therapy (32.2% vs 9.7% p < 0.05) and higher fecal calprotectin levels throughout the first year of therapy. There was no difference in the hospitalization rate for flares (p = 0.1) or IBD-related surgeries (p = 0.57). The rate of adverse events, notably herpes zoster, malignancy, and blood clot, did not differ significantly between the two groups.
conclusionUpadacitinib appears to be safe and effective for the treatment of moderate-severe UC in older adults.
Indexed as
Identifiers
41490962What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.